Drug Screening Assays, Antitumor

"Drug Screening Assays, Antitumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.

Descriptor ID	D004354
MeSH Number(s)	E01.370.225.500.388 E05.200.500.388 E05.242.417 E05.337.550.200
Concept/Terms	Drug Screening Assays, Antitumor Drug Screening Assays, Antitumor Antitumor Drug Screening Assays Cancer Drug Tests Cancer Drug Test Drug Test, Cancer Drug Tests, Cancer Test, Cancer Drug Tests, Cancer Drug Drug Screening Tests, Tumor-Specific Drug Screening Tests, Tumor Specific Antitumor Drug Screens Antitumor Drug Screen Drug Screen, Antitumor Drug Screens, Antitumor Screen, Antitumor Drug Screens, Antitumor Drug Anti-Cancer Drug Screens Anti Cancer Drug Screens Anti-Cancer Drug Screen Drug Screen, Anti-Cancer Drug Screens, Anti-Cancer Screen, Anti-Cancer Drug Screens, Anti-Cancer Drug Anticancer Drug Sensitivity Tests Tumor-Specific Drug Screening Tests Tumor Specific Drug Screening Tests Dye Exclusion Assays, Antitumor Dye Exclusion Assays, Antitumor

Below are MeSH descriptors whose meaning is more general than "Drug Screening Assays, Antitumor".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Diagnosis [E01]
Diagnostic Techniques and Procedures [E01.370]
Clinical Laboratory Techniques [E01.370.225]
Cytological Techniques [E01.370.225.500]
Drug Screening Assays, Antitumor [E01.370.225.500.388]
Investigative Techniques [E05]
Clinical Laboratory Techniques [E05.200]
Cytological Techniques [E05.200.500]
Drug Screening Assays, Antitumor [E05.200.500.388]
Cytological Techniques [E05.242]
Drug Screening Assays, Antitumor [E05.242.417]
Evaluation Studies as Topic [E05.337]
Drug Evaluation, Preclinical [E05.337.550]
Drug Screening Assays, Antitumor [E05.337.550.200]

Below are MeSH descriptors whose meaning is more specific than "Drug Screening Assays, Antitumor".

Drug Screening Assays, Antitumor
Tumor Stem Cell Assay

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Drug Screening Assays, Antitumor" by people in this website by year, and whether "Drug Screening Assays, Antitumor" was a major or minor topic of these publications.

Bar chart showing 86 publications over 25 distinct years, with a maximum of 10 publications in 2014

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1998	0	1	1
2000	0	2	2
2002	0	1	1
2003	0	3	3
2004	0	2	2
2005	0	1	1
2006	1	0	1
2007	0	4	4
2008	0	2	2
2009	1	3	4
2010	1	6	7
2011	0	6	6
2012	0	3	3
2013	0	4	4
2014	2	8	10
2015	0	5	5
2016	2	4	6
2017	0	5	5
2018	1	2	3
2019	1	3	4
2020	0	2	2
2021	0	5	5
2022	0	2	2
2023	0	2	2
2024	1	0	1

Below are the most recent publications written about "Drug Screening Assays, Antitumor" by people in Profiles.

Liu W, Mousa AAK, Hopkins AM, Wu YF, Thu KL, Campbell M, Lees SJ, Ramachandran R, Hou J. Lysophosphatidic Acid Receptor 1 (LPA1) Antagonists as Potential Migrastatics for Triple Negative Breast Cancer. ChemMedChem. 2024 Aug 19; 19(16):e202400013.

View in: PubMed
Swain RM, Sanchez A, Gutierrez DA, Varela-Ramirez A, Aguilera RJ. Thiophene derivative inflicts cytotoxicity via an intrinsic apoptotic pathway on human acute lymphoblastic leukemia cells. PLoS One. 2023; 18(12):e0295441.

View in: PubMed
Gutierrez DA, Contreras L, Villanueva PJ, Borrego EA, Mor?n-Santiba?ez K, Hess JD, DeJesus R, Larragoity M, Betancourt AP, Mohl JE, Robles-Escajeda E, Begum K, Roy S, Kirken RA, Varela-Ramirez A, Aguilera RJ. Identification of a Potent Cytotoxic Pyrazole with Anti-Breast Cancer Activity That Alters Multiple Pathways. Cells. 2022 01 12; 11(2).

View in: PubMed
Ferraris D, Lapidus R, Truong P, Bollino D, Carter-Cooper B, Lee M, Chang E, LaRossa-Garcia M, Dash S, Gartenhaus R, Choi EY, Kipe O, Lam V, Mason K, Palmer R, Williams E, Ambulos N, Kamangar F, Zhang Y, Kapadia B, Jing Y, Emadi A. Pre-Clinical Activity of Amino-Alcohol Dimeric Naphthoquinones as Potential Therapeutics for Acute Myeloid Leukemia. Anticancer Agents Med Chem. 2022; 22(2):239-253.

View in: PubMed
Nayeem N, Yeasmin A, Cobos SN, Younes A, Hubbard K, Contel M. Investigation of the Effects and Mechanisms of Anticancer Action of a Ru(II)-Arene Iminophosphorane Compound in Triple Negative Breast Cancer Cells. ChemMedChem. 2021 11 05; 16(21):3280-3292.

View in: PubMed
Borrero-Garc?a LD, Del Mar Maldonado M, Medina-Vel?zquez J, Troche-Torres AL, Velazquez L, Grafals-Ruiz N, Dharmawardhane S. Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer. BMC Cancer. 2021 Jun 01; 21(1):652.

View in: PubMed
Tilekar K, Hess JD, Upadhyay N, Bianco AL, Schweipert M, Laghezza A, Loiodice F, Meyer-Almes FJ, Aguilera RJ, Lavecchia A, C S R. Thiazolidinedione "Magic Bullets" Simultaneously Targeting PPAR? and HDACs: Design, Synthesis, and Investigations of their In Vitro and In Vivo Antitumor Effects. J Med Chem. 2021 05 27; 64(10):6949-6971.

View in: PubMed
Choodamani B, Cano Hernandez KG, Kumar S, Tony AM, Schiaffino Bustamante AY, Aguilera RJ, Schols D, Gopi Mohan C, Karki SS. Synthesis, Molecular Docking and Preliminary Antileukemic Activity of 4-Methoxybenzyl Derivatives Bearing Imidazo[2,1-b][1,3,4]thiadiazole. Chem Biodivers. 2021 Feb; 18(2):e2000800.

View in: PubMed
Gangapuram M, Eyunni S, Zhang W, Redda KK. Design and Synthesis of Tetrahydroisoquinoline Derivatives as Anti-Angiogenesis and Anti-Cancer Agents. Anticancer Agents Med Chem. 2021; 21(18):2505-2511.

View in: PubMed
Tilekar K, Upadhyay N, Hess JD, Macias LH, Mrowka P, Aguilera RJ, Meyer-Almes FJ, Iancu CV, Choe JY, Ramaa CS. Structure guided design and synthesis of furyl thiazolidinedione derivatives as inhibitors of GLUT 1 and GLUT 4, and evaluation of their anti-leukemic potential. Eur J Med Chem. 2020 Sep 15; 202:112603.

View in: PubMed

People

Explore

Similar Concepts

Top Journals